☆ 4.7 Article

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial

LANCET ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Luciano J. Costa et al.

Summary: Dara-KRd, AHCT, and MRD response-adapted consolidation lead to a high rate of MRD negativity in NDMM patients. This strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance for patients with 0 or 1 HRCA.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent A Phase 2 Measurable Residual Disease-Adapted Study

Benjamin A. Derman et al.

Summary: Treatment of newly diagnosed multiple myeloma (NDMM) with an Elo-KRd regimen has shown promising results, with high rates of stringent complete response (sCR) and/or MRD-negativity. Further evaluation is needed to determine the optimal treatment strategy and the role of autologous stem cell transplant (ASCT) in this setting.

JAMA ONCOLOGY (2022)

添加到收藏夹

Review Oncology

International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

Luciano J. Costa et al.

Summary: MRD assessment plays an increasingly important role in multiple myeloma clinical trials, but the heterogeneity in assessment and reporting methods poses challenges for data interpretation and study design. An international panel of investigators has reached consensus on including MRD in trials, recommended assessment time points, and analytical validation for MRD assays, as well as outlined parameters for reporting MRD results. The panel also provides guidance on incorporating newer approaches for residual disease detection.

LEUKEMIA (2021)

添加到收藏夹

Meeting Abstract Hematology

Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Laura Rosinol et al.

BLOOD (2021)

添加到收藏夹

Article Oncology

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial

Francesca Gay et al.

Summary: This study aimed to evaluate the efficacy and safety of different carfilzomib-based treatment approaches and maintenance therapy, showing that KRd plus ASCT demonstrated superiority in improving responses compared with other treatments, and carfilzomib plus lenalidomide as maintenance therapy improved progression-free survival compared with lenalidomide alone.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma

Pieter Sonneveld et al.

Summary: Consolidation treatment with VRD followed by lenalidomide maintenance improves PFS and depth of response in newly diagnosed patients with multiple myeloma compared to maintenance alone.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Philippe Moreau et al.

Summary: The CASSIOPEIA study compared daratumumab maintenance with observation only in newly diagnosed multiple myeloma patients, showing that daratumumab maintenance every 8 weeks for 2 years significantly reduced the risk of disease progression or death. Longer follow-up and other ongoing studies are needed to further understand the optimal daratumumab-containing post-ASCT maintenance treatment strategy.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Hematology

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Peter M. Voorhees et al.

BLOOD (2020)

添加到收藏夹

Article Hematology

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Jagoda K. Jasielec et al.

BLOOD (2020)

添加到收藏夹

Article Hematology

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michele Cavo et al.

LANCET HAEMATOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

Edward A. Stadtmauer et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios A. Dimopoulos et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

Graham H. Jackson et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

Philip L. McCarthy et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial

L. Rosinol et al.

LEUKEMIA (2017)

添加到收藏夹

Article Hematology

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma

Dharshan Sivaraj et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)

添加到收藏夹

Review Oncology

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Shaji Kumar et al.

LANCET ONCOLOGY (2016)

添加到收藏夹

Article Hematology

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

Bruno Paiva et al.

BLOOD (2012)

添加到收藏夹

Article Oncology

EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols

T. Kalina et al.

LEUKEMIA (2012)

添加到收藏夹

Article Medicine, General & Internal

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Michel Attal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Medicine, General & Internal

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Philip L. McCarthy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Hematology

Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma

Michel Attal et al.

BLOOD (2006)

添加到收藏夹

Article Oncology

International uniform response criteria for multiple myeloma

B. G. M. Durie et al.

LEUKEMIA (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.